The IL1R1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-mediated genetic disruption of the IL1R1 gene in the human A-549 lung adenocarcinoma cell line. This polyclonal knockout cell population provides a loss-of-function model to dissect interleukin-1 (IL-1) signaling, eliminating IL1R1 receptor expression without selection of a single clonal isolate. The heterogeneous population retains the polyclonal nature, allowing studies of pooled knockout effects on inflammatory pathways.
A-549 cells are a widely employed model of human lung adenocarcinoma, derived from an alveolar basal epithelial cell origin. They exhibit characteristic epithelial morphology and are extensively used to investigate lung cancer biology, including mechanisms of tumor progression, metastasis, drug resistance, and epithelial-mesenchymal transition (EMT). The A-549 line provides a relevant context for examining how the IL-1 signaling axis influences the malignant phenotype of lung epithelial cells.
IL1R1 encodes the type I interleukin-1 receptor, a central mediator of pro-inflammatory signaling. Ligand binding by IL-1?? or IL-1?? induces heterodimerization with IL1RAP, which recruits the adaptor MyD88 and activates IRAK4 and IRAK1. These kinases trigger TRAF6 oligomerization and ubiquitination, leading to TAK1 activation, which phosphorylates the IKK complex, driving NF-??B nuclear translocation, and also stimulates p38 and JNK MAP kinases. Downstream this induces transcription of pro-inflammatory cytokines (IL-6, CXCL8/IL-8), COX-2 (PTGS2), and MMPs. The cascade is competitively inhibited by the endogenous antagonist IL-1Ra. Key interacting factors such as MyD88, IRAK1, IRAK4, TRAF6, TAB2, and TAK1 form the receptor-proximal signaling complex essential for signal relay.
In the A-549 lung adenocarcinoma model, IL-1 signaling has been implicated in promoting an inflammatory tumor microenvironment that supports cancer progression, invasion, and chemoresistance. This polyclonal IL1R1 knockout population enables researchers to uncouple the direct effects of IL-1 on lung epithelial cells from paracrine stromal influences. By eliminating IL1R1, the cascade that activates NF-??B and AP-1 transcription factors is interrupted, blunting the induction of effectors such as IL-6, IL-8, and COX-2, which are known to drive tumor-associated inflammation and EMT. Consequently, this model is a valuable platform for dissecting how autocrine and paracrine IL-1 signals modulate lung cancer cell plasticity and therapeutic vulnerability.
Typical applications include dissecting IL-1-driven signaling networks in lung cancer, assessing inflammation-dependent EMT regulation, and evaluating cytokine-mediated drug resistance. These cells are suitable for IL-1?? stimulation followed by Western blot detection of IL1R1 and phospho-proteins (e.g., phospho-p65 NF-??B, phospho-p38, phospho-JNK), RT-qPCR of target genes (IL-6, IL-8), NF-??B reporter assays, and ELISA-based cytokine quantification. Migration and invasion assays probe IL1R1??s role in metastatic behavior, while RNA-seq and co-immunoprecipitation enable global and protein interaction analyses. For further details, please contact Ascent Research.
